April 01, 2025

FDA Monthly Round-Up: Key March Updates

March’s FDA approvals feature new biosimilars, first-in-class therapies, expanded indications, and diagnostic innovations across allergy, cardiology, gastroenterology, infectious diseases, and more.

Conexiant

April 01, 2025

FDA Approves Freeze-Dried Jynneos Vaccine

Bavarian Nordic’s freeze-dried Jynneos vaccine offers logistical advantages over the liquid-frozen version, supporting long-term U.S. stockpiling and public health preparedness.

Conexiant

April 01, 2025

Cemiplimab Effective for Advanced cSCC

Meta-analysis of 19 studies reveals promising 54.5% objective response rate and manageable safety profile for PD-1 inhibitor in treating advanced cutaneous squamous cell carcinoma.

Conexiant

March 31, 2025

Tariff Threat: Drugs Could Cost U.S. $750M More

New research reveals 25% tariffs on Canadian pharmaceuticals would impact critical medications, strain supply chains, and potentially increase costs—with 28 drugs having no alternative suppliers.

Conexiant

March 26, 2025

Anesthesiologist Facing Attempted Murder Charges

An anesthesiologist has been apprehended in Hawaii after allegedly assaulting his spouse at a popular hiking location, resulting in the closure of the Nu'uanu Pali State Wayside.

Conexiant

March 25, 2025

Microplastics: Chewing Gum May Release Particles Into Saliva

"Surprisingly, both synthetic and natural gums had similar amounts of microplastics released when we chewed them."

Conexiant

March 24, 2025

TPT Lowers Tuberculosis Risk in Rheumatic Patients

TPT decreased the overall risk of tuberculosis disease in patients with rheumatic diseases, with a 76% risk reduction observed in certain subgroups, researchers reported.

Conexiant

March 21, 2025

Vutrisiran Receives FDA Nod for ATTR Amyloidosis With Cardiomyopathy

The FDA approves vutrisiran (Amvuttra) as the first RNAi therapeutic to reduce cardiovascular events and mortality in adults with transthyretin-mediated (ATTR) amyloidosis with cardiomyopathy.

Conexiant

March 21, 2025

FDA Approves Guselkumab for Crohn’s Disease

The FDA has approved guselkumab (TREMFYA®) for moderately to severely active Crohn’s disease, supported by Phase 3 trial data showing clinical and endoscopic superiority over ustekinumab.

Conexiant